Screening of Mineralogenic and Osteogenic Compounds in Zebrafish-Tools to Improve Assay Throughput and Data Accuracy.
Joana Teixeira RosaMarco TarascoPaulo Jorge GavaiaMaria Leonor CancelaVincent LaizéPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Bone disorders affect millions of people worldwide and treatments currently available often produce undesirable secondary effects or have limited efficacy. It is therefore of the utmost interest for patients to develop more efficient drugs with reduced off-target activities. In the long process of drug development, screening and preclinical validation have recently gained momentum with the increased use of zebrafish as a model organism to study pathological processes related to human bone disorders, and the development of zebrafish high-throughput screening assays to identify bone anabolic compounds. In this review, we provided a comprehensive overview of the literature on zebrafish bone-related assays and evaluated their performance towards an integration into screening pipelines for the discovery of mineralogenic/osteogenic compounds. Tools available to standardize fish housing and feeding procedures, synchronize embryo production, and automatize specimen sorting and image acquisition/analysis toward faster and more accurate screening outputs were also presented.
Keyphrases
- drug induced
- bone mineral density
- high throughput
- mesenchymal stem cells
- soft tissue
- bone loss
- end stage renal disease
- postmenopausal women
- endothelial cells
- chronic kidney disease
- systematic review
- newly diagnosed
- deep learning
- prognostic factors
- small molecule
- machine learning
- mass spectrometry
- mental health
- induced pluripotent stem cells